Abstract:Abstract Virus-like particles (VLPs) are virus-derived structures made up of one or more different molecules with the ability to self-assemble, mimicking the form and size of a virus particle but lacking the genetic material so they are not capable of infecting the host cell. Expression and self-assembly of the viral structural proteins can take place in various living or cell-free expression systems after which the viral structures can be assembled and reconstructed. VLPs are gaining in popularity in the field of preventive medicine and to date, a wide range of VLP-based candidate vaccines have been developed for immunization against various infectious agents, the latest of which is the vaccine against SARS-CoV-2, the efficacy of which is being evaluated. VLPs are highly immunogenic and are able to elicit both the antibody- and cell-mediated immune responses by pathways different from those elicited by conventional inactivated viral vaccines. However, there are still many challenges to this surface display system that need to be addressed in the future. VLPs that are classified as subunit vaccines are subdivided into enveloped and non- enveloped subtypes both of which are discussed in this review article. VLPs have also recently received attention for their successful applications in targeted drug delivery and for use in gene therapy. The development of more effective and targeted forms of VLP by modification of the surface of the particles in such a way that they can be introduced into specific cells or tissues or increase their half-life in the host is likely to expand their use in the future. Recent advances in the production and fabrication of VLPs including the exploration of different types of expression systems for their development, as well as their applications as vaccines in the prevention of infectious diseases and cancers resulting from their interaction with, and mechanism of activation of, the humoral and cellular immune systems are discussed in this review.

Virus-like Particles: Potential Veterinary Vaccine Immunogens.

Virus-like particles: The new frontier of vaccines for animal viral infections

Virus-like particles: promising platforms with characteristics of DIVA for veterinary vaccine design.

Progress and hurdles in the development of influenza virus-like particle vaccines for veterinary use

Virus-like Particle Vaccines and Platforms for Vaccine Development

Advances in the study of virus-like particles as vaccines

Virus-like particles in poultry disease: an approach to effective and safe vaccination

[Current research status of virus-like particle vaccine]

Virus-like particles as powerful vaccination strategy against human viruses

Self-assembly of virus-like particles of canine parvovirus capsid protein expressed from Escherichia coli and application as virus-like particle vaccine

Virus-like particles vaccines based on glycoprotein E0 and E2 of bovine viral diarrhea virus induce Humoral responses

Research Progress of Murine Polyomavirus Virus-like Particle and Its Application in Vaccine Development

High-yield production of canine parvovirus virus-like particles in a baculovirus expression system

Virus-Like Particle Vaccines Against Respiratory Viruses and Protozoan Parasites.

Virus-like particle-based vaccine development using Escherichia coil expression system

Virus-like particles: preparation, immunogenicity and their roles as nanovaccines and drug nanocarriers

Recent Progress on the Versatility of Virus-Like Particles

Canine Parvovirus VP2 Protein Expressed in Silkworm Pupae Self-Assembles into Virus-Like Particles with High Immunogenicity

Construction And Immunogenicity Of Novel Chimeric Virus-Like Particles Bearing Antigens Of Infectious Bronchitis Virus And Newcastle Disease Virus

Virus-Like Particle Vaccine Induces Protective Immunity Against Homologous and Heterologous Strains of Influenza Virus

Progress in developing virus-like particle influenza vaccines.